CRNX - Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder | Benzinga
On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary endpoints in acromegaly patients.
Acromegaly is a rare condition where the body produces too much growth hormone, causing body tissues and bones to grow more quickly. Over time, this leads to abnormally large hands and feet and many other symptoms.
The PATHFNDR-1 was a randomized, double-blind, placebo-controlled 36-week treatment period followed by an optional open-label extension ...